Dr. Fujiwara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm and Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-2300
Summary
- Hematology/Oncology fellow at Roswell Park Comprehensive Cancer Center
Education & Training
- University at BuffaloFellowship, Hematology and Medical Oncology, 2023 - 2026
- Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2020 - 2023
- The Cancer Institute Hospital of Japanese Foundation for Cancer ResearchMedical Oncology, Medical Oncology, 2019 - 2020
- Musashino Red Cross HospitalMedical Oncology, Medical Oncology, 2018 - 2020
- Musashino Red Cross HospitalInternal Medicine, 2017 - 2018
- Keio University HospitalTwo-year internship, 2015 - 2017
- Keio Gujuku University School of MedicineClass of 2015
Certifications & Licensure
- NY State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- Japanese Society of Internal MedicineBoard Certification
- Japanese Society of Medical OncologyDiplomate, Subspecialty Board of Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha membership Alpha Omega Alpha Honor Medical Society, 2023
- Most Outstanding Poster Award Annual Meeting of Japanese Society of Hospital General Medicine, 2018
- Keio University Scholarship Keio University, 2012
Publications & Presentations
PubMed
- Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and me...Riona Aburaki, Yu Fujiwara, Kohei Chida, Nobuyuki Horita, Misako Nagasaka
Cancer Treatment Reviews. 2024-12-01 - Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and...Jonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, Isabella Michelon, Caio Castro
JCO Precision Oncology. 2024-11-01 - Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib
Journal of Thoracic Oncology. 2024-09-10
Press Mentions
- Experts Available and Research to Be Presented in Bladder Cancer, Disparities in Cancer and Other Areas at the 2021 ASCO Annual MeetingMay 19th, 2021
- Adverse Events up with Immune Checkpoint Blockade Added to Periop Cancer TherapyDecember 8th, 2023
Professional Memberships
- Member
- Society for Immunotherapy of CancerMember
- European Society of Medical OncologyMember
- Japanese Society of Medical OncologyMember
- Japanese Society of Internal MedicineMember
- Japanese Cancer AssociationMember
- Member
Other Languages
- Japanese
External Links
- Google Scholarhttps://scholar.google.co.jp/citations?user=IfqWWvYAAAAJ&hl=ja
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: